Summit Therapeutics Stock Forecast

Stock Price Forecast

The 14 analysts that cover Summit Therapeutics stock have a consensus rating of "Buy" and an average price target of $32.07, which forecasts a 69.50% increase in the stock price over the next year. The lowest target is $12 and the highest is $44.

Price Target: $32.07 (+69.50%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$12	$32.07	$40	$44
Change	-36.58%	+69.50%	+111.42%	+132.56%

Analyst Ratings

The average analyst rating for Summit Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26
Strong Buy	9	9	8	7	7	7
Buy	5	5	4	4	4	4
Hold	1	2	3	3	3	4
Sell	2	2	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	17	18	16	15	15	16

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Clara Dong Jefferies	Jefferies	Strong Buy → Hold Downgrades $42 → $15	Strong Buy → Hold	Downgrades	$42 → $15	-20.72%	Mar 16, 2026
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $40 → $30	Strong Buy	Maintains	$40 → $30	+58.56%	Feb 24, 2026
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $40	Strong Buy	Reiterates	$40	+111.42%	Feb 2, 2026
Reni J. Benjamin Citizens	Citizens	Buy Reiterates $40	Buy	Reiterates	$40	+111.42%	Jan 30, 2026
Etzer Darout Barclays	Barclays	Sell → Hold Upgrades $16 → $18	Sell → Hold	Upgrades	$16 → $18	-4.86%	Dec 17, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

9.71M

Revenue Next Year

104.92M

from 9.71M

980.65%

from 9.71M

EPS This Year

-1.02

from -1.44

EPS Next Year

-1.01

from -1.02

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	1.81M	705.00K	-	-	-	9.71M	104.92M
Revenue Growth	110.35%	-61.03%	-	-	-	-	980.65%
EPS	-0.96	-0.41	-0.99	-0.31	-1.44	-1.02	-1.01
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	18	16

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	61.0M	377.9M
Avg	9.7M	104.9M
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027
High	-	3,792.0%
Avg	-	980.6%
Low	-	-

EPS Forecast

EPS	2026	2027
High	-0.60	-0.61
Avg	-1.02	-1.01
Low	-1.60	-1.65

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.